Xencor reaches milestone in technology license agreement with Boehringer
The amount of the milestone payment and the oncology drug target have not been disclosed. The payment was generated due to a regulatory submission to commence Phase I
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.
Under the collaboration, the companies will produce ADCs by integrating PolyTherics’ proprietary TheraPEG linker technology with Spirogen’s pyrrolobenzodiazepines (PBDs) cytotoxic agents. The companies will then evaluate the potency
Codexis Pharmaceuticals senior vice president Peter Seufer-Wasserthal said the Codexis technology has delivered solid results including the reduction in production costs for boceprevir. Codexis employed its proprietary CodeEvolver